Lars Husmann1, Bert-Ram Sah2, Alexandra Scherrer3, Irene A Burger2, Paul Stolzmann2, Rainer Weber3, Zoran Rancic4, Dieter Mayer4, Barbara Hasse. 1. Division of Nuclear Medicine, Department of Medical Radiology, University Hospital of Zurich, Zurich, Switzerland lars.husmann@usz.ch. 2. Division of Nuclear Medicine, Department of Medical Radiology, University Hospital of Zurich, Zurich, Switzerland. 3. Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich, Zurich, Switzerland; and. 4. Clinic for Cardiovascular Surgery, University Hospital and University of Zurich, Zurich, Switzerland.
Abstract
UNLABELLED: The aim of this study was to evaluate the clinical value of PET/CT with (18)F-FDG for therapy control in patients with prosthetic vascular graft infections (PVGIs). METHODS: In this single-center, observational, prospective cohort study, 25 patients with a median age of 66 y (range, 48-81 y) who had a proven PVGI were included. Follow-up (18)F-FDG PET/CT was performed at a median of 170 d (range, 89-249 d) after baseline examination. Two independent and masked interpreters measured maximum standardized uptake values to quantify metabolic activity and analyzed whole-body datasets for a secondary diagnosis (i.e., infectious foci not near the graft). The metabolic activity of the graft was correlated with clinical information and 2 laboratory markers (C-reactive protein and white blood cell count). RESULTS: (18)F-FDG PET/CT had an impact on management in all patients. In 19 of 25 patients (76%), antibiotic treatment was continued because of the results of follow-up (18)F-FDG PET/CT. Antibiotic treatment was stopped or changed in 8% and 16% of patients, respectively. In 8 patients (32%), additional incidental findings were detected on follow-up (18)F-FDG PET/CT and had a further impact on patient management. Only in a subgroup of patients with PVGI and no other sites of infection was a significant correlation found between the difference in C-reactive protein at the time of baseline and follow-up (18)F-FDG PET/CT and the difference in maximum standardized uptake value (n = 11; R(2) = 0.67; P = 0.002). CONCLUSION: (18)F-FDG PET/CT represents a useful tool in therapy monitoring of PVGI and has an impact on patient management.
UNLABELLED: The aim of this study was to evaluate the clinical value of PET/CT with (18)F-FDG for therapy control in patients with prosthetic vascular graft infections (PVGIs). METHODS: In this single-center, observational, prospective cohort study, 25 patients with a median age of 66 y (range, 48-81 y) who had a proven PVGI were included. Follow-up (18)F-FDG PET/CT was performed at a median of 170 d (range, 89-249 d) after baseline examination. Two independent and masked interpreters measured maximum standardized uptake values to quantify metabolic activity and analyzed whole-body datasets for a secondary diagnosis (i.e., infectious foci not near the graft). The metabolic activity of the graft was correlated with clinical information and 2 laboratory markers (C-reactive protein and white blood cell count). RESULTS: (18)F-FDG PET/CT had an impact on management in all patients. In 19 of 25 patients (76%), antibiotic treatment was continued because of the results of follow-up (18)F-FDG PET/CT. Antibiotic treatment was stopped or changed in 8% and 16% of patients, respectively. In 8 patients (32%), additional incidental findings were detected on follow-up (18)F-FDG PET/CT and had a further impact on patient management. Only in a subgroup of patients with PVGI and no other sites of infection was a significant correlation found between the difference in C-reactive protein at the time of baseline and follow-up (18)F-FDG PET/CT and the difference in maximum standardized uptake value (n = 11; R(2) = 0.67; P = 0.002). CONCLUSION: (18)F-FDG PET/CT represents a useful tool in therapy monitoring of PVGI and has an impact on patient management.
Authors: Lars Husmann; Martin W Huellner; Nadia Eberhard; Bruno Ledergerber; Marisa B Kaelin; Alexia Anagnostopoulos; Ken Kudura; Irene A Burger; Carlos-A Mestres; Zoran Rancic; Barbara Hasse Journal: Sci Rep Date: 2021-03-03 Impact factor: 4.379
Authors: Chiara Lauri; Alberto Signore; Andor W J M Glaudemans; Giorgio Treglia; Olivier Gheysens; Riemer H J A Slart; Roberto Iezzi; Niek H J Prakken; Eike Sebastian Debus; Susanne Honig; Anne Lejay; Nabil Chakfé Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-04 Impact factor: 10.057
Authors: Lars Husmann; Nadia Eberhard; Martin W Huellner; Bruno Ledergerber; Anna Mueller; Hannes Gruenig; Michael Messerli; Carlos-A Mestres; Zoran Rancic; Alexander Zimmermann; Barbara Hasse Journal: Sci Rep Date: 2021-07-02 Impact factor: 4.379